OLMA Olema Pharmaceuticals, Inc.


$ 7.94 $ -0.12 (-1.49 %)    

Thursday, 13-Nov-2025 15:59:58 EST
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ na
$ 7.97
$ 7.90 x 15
$ 8.85 x 1
-- - --
$ 2.86 - $ 12.26
1,506,942
na
680.89M
$ 1.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 olema-pharmaceuticals-q3-eps-049-misses-045-estimate

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate ...

 olema-pharmaceuticals-to-present-a-trial-in-progress-poster-for-its-phase-3-opera-02-trial-at-2025-san-antonio-breast-cancer-symposium

Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical com...

 hc-wainwright--co-reiterates-buy-on-olema-pharmaceuticals-maintains-28-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $28 pri...

 reported-saturday-olema-oncology-reports-155-month-median-progression-free-survival-with-palazestrant-plus-ribociclib-in-er-positive-her2-negative-metastatic-breast-cancer-at-esmo-2025

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroupsMedian PFS w...

 guggenheim-initiates-coverage-on-olema-pharmaceuticals-with-buy-rating-announces-price-target-of-20

Guggenheim analyst Brad Canino initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announces Pri...

 oppenheimer-maintains-outperform-on-olema-pharmaceuticals-maintains-22-price-target

Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and maintains $22 price ...

 jp-morgan-maintains-overweight-on-olema-pharmaceuticals-raises-price-target-to-29

JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and raises the price target fr...

 citigroup-maintains-buy-on-olema-pharmaceuticals-raises-price-target-to-21

Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target fro...

 olema-pharmaceuticals-q2-eps-051-misses-038-estimate

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate ...

 goldman-sachs-maintains-buy-on-olema-pharmaceuticals-lowers-price-target-to-18

Goldman Sachs analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from ...

 oppenheimer-maintains-outperform-on-olema-pharmaceuticals-lowers-price-target-to-22

Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and lowers the price tar...

 olema-pharmaceuticals-q1-eps-036-beats-051-estimate

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-reiterates-buy-on-olema-pharmaceuticals-maintains-30-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $30 pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION